Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche/Igen settlement?

This article was originally published in The Gray Sheet

Executive Summary

Igen hires Goldman Sachs as strategic advisor, heightening pressure on Roche as the firms discuss a possible settlement of patent litigation and Igen weighs options to maximize shareholder value - including other development partners for Igen's Origen diagnostics technology. Gaithersburg, Maryland-based Igen was awarded $505 mil. by a Maryland federal court in January after Igen filed suit in 1997, charging Roche with breaching an Origen license agreement (1"The Gray Sheet" Jan. 14, 2002, p. 31.) Roche, which said it would appeal the decision, confirms that settlement talks are ongoing...

You may also be interested in...



Roche To Appeal $505 Mil. Jury Decision Granting Igen Elecsys Rights

Igen International will gain the rights to Roche Diagnostic's Elecsys diagnostic product line under a $505 mil. verdict reached Jan. 10 in Maryland federal court

Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.

Industry Asks If Small Business Loan Relief Applies To Companies With Equity Investors

A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.

UsernamePublicRestriction

Register

MT016867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel